Keyword : targeted therapy
ASCO 2026: key trials
Cardiovascular complications of modern therapy in oncohematology: the role of the cardiologist in multidisciplinary patient managementAuthor:Nemish I.L. Дата: 2026-10-26
Hold the world! New opportunities for targeted therapy HR+ / HER2− mBC
Systemic treatment of locally advanced and metastatic EGFR-mutated NSCLC. What’s new?Т. 16, №2 (62)
Therapeutic options for breast cancer with low HER2/NEU expressionAuthors: Chovgan O.E. Samuseva A.A. Lyalkin S.A. Т. 15, №4 (60)
Treatment with tyrosine kinase inhibitors in patients with metastatic differentiated thyroid cancer refractory to radioiodine therapyAuthors: Solodiannykova O.I. Danylenko V.V. Т. 15, №4 (60)
Lung oncology: a new era in therapy
Management strategy for gastrointestinal stromal tumors (GIST): current status and future perspectivesAuthors: Kondratskyi Yu.M. Koval N.O. Kolesnyk A.V. Kozak E.O.... Т. 15, №2 (58)
Side effects of iodine-negative thyroid cancer targeted therapyAuthors: Solodyannikova O.I. Bankovska N.V. Danylenko V.V. Turitsyna V.L. Т. 15, №1 (57)
From theory to practice. The art of lung cancer treatment
Zirabev as a representative of the largest family of biosimilars in oncology
Sorafenib in the treatment of iodine-negative differentiated thyroid cancerAuthors: Solodiannykova O.I. Kmetyuk Y.V. Stolyarova O.Yu. Danylenko V.V.... Т. 14, №2 (54)
Induction targeted therapy with tyrosine kinase inhibitors in the treatment of EGFR-positive non-small cell lung cancer. Clinical case and discussion of features of therapeutic «targeted» tumor pathomorphosisAuthors: Sukhoversha O.A. Tsyhankov K.V. Kuzhevskyi I.V. Koval S.S. Т. 13, № 2 (50)
Treatment of patients with Hodgkin’s lymphoma after progression: chemosensitivity, transplantation and targeted drugsAuthors: Rudiuk T. Novosad O. Kryachok I. Т. 12, № 1-2 (45-46)
The role of targeted therapy in the treatment of patients with EGFR+ mutations of lung cancer (review)Authors: Kolesnik O.P. Shevchenco A.I. Kadzhoian A.V. Kuzmenko V.A.... Т. 8, № 3 (31) 2018
